Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia.
作者信息
Daver Naval, Jonas Brian A, Medeiros Bruno C, Patil Upen, Yan Mark
机构信息
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
UC Davis Comprehensive Cancer Center, Sacramento, CA, USA.
出版信息
Leuk Lymphoma. 2022 Nov;63(11):2711-2714. doi: 10.1080/10428194.2022.2092853. Epub 2022 Jul 14.
Abstract
摘要
Zotero 插件